Investigation of CRBN-expression phenotypes and related pathways in stage 4 cancer could reveal the role of CRBN in late stage of lung cancer and provide supportive evidences for the clinical use of CRBN and CRBN-related pathways as therapeutic target or prognostic marker for stage for patients. This evidence concerns the gene CRBN and lung carcinoma.